OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
January 02, 2008
The replacement of a IgG ELISA assay with an SPR-based test can shorten the production workflow by one day.
The recombinant approach lends itself to the production of an inexpensive and effective vaccine at large scale.
Potential interference with maternally-derived antibodies makes most vaccines less effective in the neonate.
Human HBV can be grouped into eight genotypes, which differ by at least 8%.
Microstructured transdermal systems can deliver a vaccine in close proximity to the antigen-presenting cells in the epidermis.